The U.S. veterinary eye care market size was estimated at USD 1.75 Billion in 2025 and is projected to reach USD 2.71 billion by 2033, growing at a CAGR of 5.6% from 2025 to 2033. The market is advancing owing to factors such as expanding veterinary eye care avenues, increasing advocacy for rationale use of antibiotics, growing involvement of veterinary professionals in spreading awareness, and technological advancements in veterinary eye care.
The veterinary eye care sector in the U.S. is experiencing significant growth, driven by advancements in surgical techniques, genetic research, and diagnostic technologies. These developments are expanding the scope of eye care for animals, offering new hope for conditions that were once considered untreatable.
A notable example is the use of retinal reattachment surgery, or retinopexy, conducted in January 2025, by UC Davis, to address retinal tears in dogs. This procedure involves replacing the natural gel in the eye with silicone oil to reposition the retina, effectively restoring vision in affected animals. Such specialized surgeries are becoming more accessible, thanks to improvements in surgical equipment and training.
Genetic research is also playing a pivotal role in veterinary eye care. Studies such as the March 2025 article published by dvm360 have identified specific genetic mutations responsible for conditions such as progressive retinal atrophy (PRA) in dogs. For instance, a 3-base pair deletion in the GTPBP2 gene has been linked to PRA, providing a basis for genetic testing and informed breeding decisions. This approach aims to prevent the hereditary transmission of such conditions, thereby reducing their prevalence in future generations.
In terms of treatment options, the use of latanoprost in managing glaucoma in cats highlights the complexities of veterinary ophthalmology. While latanoprost has shown efficacy in lowering intraocular pressure in cats, its limitations underscore the need for ongoing research and development of more effective therapies tailored to feline physiology.
Furthermore, the adoption of laser technology for treating canine eyelid tumors represents a significant advancement in non-invasive surgical techniques. As per March 2025 article published by dvm360, laser treatments offer precision and reduced recovery times compared to traditional methods, enhancing the overall treatment experience for both pets and their owners.
Collectively, these innovations are contributing to a dynamic and rapidly evolving veterinary ophthalmology landscape. As the field continues to progress, it holds the promise of improved outcomes for animals suffering from a range of ocular conditions, reflecting a broader trend toward specialized and compassionate veterinary care.
This product will be delivered within 1-3 business days.
The veterinary eye care sector in the U.S. is experiencing significant growth, driven by advancements in surgical techniques, genetic research, and diagnostic technologies. These developments are expanding the scope of eye care for animals, offering new hope for conditions that were once considered untreatable.
A notable example is the use of retinal reattachment surgery, or retinopexy, conducted in January 2025, by UC Davis, to address retinal tears in dogs. This procedure involves replacing the natural gel in the eye with silicone oil to reposition the retina, effectively restoring vision in affected animals. Such specialized surgeries are becoming more accessible, thanks to improvements in surgical equipment and training.
Genetic research is also playing a pivotal role in veterinary eye care. Studies such as the March 2025 article published by dvm360 have identified specific genetic mutations responsible for conditions such as progressive retinal atrophy (PRA) in dogs. For instance, a 3-base pair deletion in the GTPBP2 gene has been linked to PRA, providing a basis for genetic testing and informed breeding decisions. This approach aims to prevent the hereditary transmission of such conditions, thereby reducing their prevalence in future generations.
In terms of treatment options, the use of latanoprost in managing glaucoma in cats highlights the complexities of veterinary ophthalmology. While latanoprost has shown efficacy in lowering intraocular pressure in cats, its limitations underscore the need for ongoing research and development of more effective therapies tailored to feline physiology.
Furthermore, the adoption of laser technology for treating canine eyelid tumors represents a significant advancement in non-invasive surgical techniques. As per March 2025 article published by dvm360, laser treatments offer precision and reduced recovery times compared to traditional methods, enhancing the overall treatment experience for both pets and their owners.
Collectively, these innovations are contributing to a dynamic and rapidly evolving veterinary ophthalmology landscape. As the field continues to progress, it holds the promise of improved outcomes for animals suffering from a range of ocular conditions, reflecting a broader trend toward specialized and compassionate veterinary care.
U.S. Veterinary Eye Care Market Report Segmentation
This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. veterinary eye care market report based on animal, product, indication, and distribution channel:Animal Outlook (Revenue, USD Million, 2021-2033)
- Canine
- Feline
- Equine
- Bovine
- Others
Product Outlook (Revenue, USD Million, 2021-2033)
- Devices & Instruments
- Medications
Indication Outlook (Revenue, USD Million, 2021-2033)
- Eyelid Abnormalities
- Cataract
- Glaucoma
- Retinal Complications
- Uveitis
- Conjunctivitis
- Corneal Complications
- Other Indications
Distribution Channel Outlook (Revenue, USD Million, 2021-2033)
- Veterinary Hospitals & Clinics
- Specialty Stores
- E-Commerce
- Other Distribution Channels
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Veterinary Eye Care Market Variable Trends & Scope
Chapter 4. U.S. Veterinary Eye Care Market: Animal Estimates & Trend Analysis
Chapter 5. U.S. Veterinary Eye Care Market: Product Estimates & Trend Analysis
Chapter 6. U.S. Veterinary Eye Care Market: by Indication Estimates & Trend Analysis
Chapter 7. U.S. Veterinary Eye Care Market: by Distribution Channel Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players profiled in this U.S. Veterinary Eye Care market report include:- erck & Co., Inc.
- n-Vision GmbH
- orgensen Laboratories
- KC Technologies Inc.
- ccutome Inc.
- echra Pharmaceuticals
- ausch & Lomb Incorporated
- oetis Services LLC.
- eva Sante Animale
- andoz
- oehringer Ingelheim
- -Med Animal Health
- ridex Corporation
- axter (Welch Allyn)
- ptoMed
- eichert, Inc.
- ccuity
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | September 2025 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 1.75 Billion |
| Forecasted Market Value ( USD | $ 2.71 Billion |
| Compound Annual Growth Rate | 5.6% |
| Regions Covered | United States |
| No. of Companies Mentioned | 18 |
